Stenabolic (SR9009) for Metabolic Enhancement & Circadian Rhythm — Weight & Metabolism

Overview

SR9009 (Stenabolic) is a synthetic agonist of the Rev-ErbA nuclear receptor, developed by Professor Thomas Burris and colleagues at the Scripps Research Institute. Rev-ErbA (specifically Rev-Erbα and Rev-Erbβ) are nuclear receptors that function as core components of the molecular circadian clock, playing critical roles in the regulation of metabolic gene expression, lipid homeostasis, inflammation, and mitochondrial biogenesis. SR9009 was first described in a landmark 2012 publication (Solt et al., Nature 2012; PMID: 22460951) demonstrating that pharmacological activation of Rev-Erbα in mice significantly altered circadian behavior and metabolism, reducing fat mass, improving exercise endurance by 50%, decreasing plasma cholesterol and triglycerides, and increasing mitochondrial content in skeletal muscle. These striking results led to SR9009 being marketed in performance-enhancement communities as "exercise in a bottle," similar to Cardarine. However, a critical pharmacological limitation severely undermines the practical utility of oral SR9009: its oral bioavailability is extremely poor, estimated at less than 2% in animal models. This means that orally administered SR9009 is almost entirely destroyed by first-pass hepatic metabolism before reaching systemic circulation. The dramatic effects observed in the original mouse studies were achieved using intraperitoneal injection, bypassing the GI tract entirely. Subsequent research confirmed that oral administration of SR9009 produced negligible plasma levels and minimal biological effects. Despite this critical limitation, SR9009 continues to be widely sold and consumed orally in the gray market. No human clinical trials have been conducted. No pharmacokinetic, safety, or efficacy data exist in humans. The compound is NOT FDA-approved, has no IND application, and its legal status varies by jurisdiction. It is not currently explicitly prohibited by WADA but is considered at risk of future prohibition.

Indications

• Preclinical research tool for Rev-ErbA receptor biology (PMID: 22460951)
• Investigation of circadian clock modulation effects on metabolism
• Research into metabolic syndrome treatment via circadian gene regulation
• Investigation of exercise mimetic compounds (preclinical)
• No clinical development initiated — poor oral bioavailability limits utility

Mechanism of Action

SR9009 taken orally is almost entirely destroyed by first-pass hepatic metabolism, with bioavailability <2% in animal models. Sublingual administration has been attempted but not validated. The dramatic effects seen in mouse studies used intraperitoneal injection, bypassing this limitation

Dosing

Evidence Grade

GRADE D

Safety & Contraindications

• Extremely poor oral bioavailability (<2%) — oral dosing likely ineffective
• Original mouse study results achieved with intraperitoneal injection, NOT oral dosing
• NO human clinical trials — all safety data is preclinical
• Unknown human metabolism, drug interactions, and adverse effects
• Marketed as 'exercise in a bottle' based on misrepresented mouse data
• Very short half-life (~4 hours in mice) requires frequent dosing
• Unknown effects on human circadian rhythm disruption
• Gray-market products of unknown purity — no quality assurance
• Potential hepatic effects due to Rev-Erb expression in liver
• Unknown long-term safety profile
• Not currently WADA prohibited but may be added in future